Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

• Domperidone is now contraindicated in confirmed or suspected phaeochromocytoma due to risk of severe hypertensive episodes from catecholamine release
• All domperidone product information has been updated to reflect this contraindication; clinicians should screen for phaeochromocytoma symptoms before prescribing
• Consider alternative antiemetics in patients with unexplained hypertension or clinical features suggestive of phaeochromocytoma

The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episode…

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.